Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Curr Cardiol Rep ; 13(5): 439-50, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21800098

ABSTRACT

The P2Y12-ADP receptor antagonists are the cornerstone of oral antiplatelet therapy in the secondary prevention of coronary artery disease, especially after acute coronary syndrome or percutaneous coronary intervention. Currently, the therapeutic agents available to block the receptor include clopidogrel and prasugrel; ticagrelor is not available everywhere. Clopidogrel was the gold standard, but recently it has been challenged by prasugrel and ticagrelor. One pitfall of clopidogrel is that in some patients it cannot induce optimal platelet reactivity inhibition in connection with several factors, including some genetic polymorphisms of enzymes participating in its bioabsorption or metabolism. This variability of response can be evaluated by platelet reactivity monitoring. This comprehensive review provides the available data regarding the genotypic and phenotypic interaction with the response to P2Y12-ADP receptor antagonists and discusses the concept of personalized antiplatelet therapy based on a genotypic or phenotypic profile.


Subject(s)
Adenosine/analogs & derivatives , Coronary Artery Disease/drug therapy , Piperazines/pharmacology , Platelet Aggregation Inhibitors/pharmacology , Purinergic P2 Receptor Antagonists/pharmacology , Thiophenes/pharmacology , Ticlopidine/analogs & derivatives , Adenosine/administration & dosage , Adenosine/pharmacology , Clopidogrel , Coronary Artery Disease/metabolism , Female , Genetic Association Studies , Humans , Male , Piperazines/administration & dosage , Platelet Aggregation Inhibitors/administration & dosage , Prasugrel Hydrochloride , Purinergic P2 Receptor Antagonists/administration & dosage , Receptors, Purinergic P2Y12/drug effects , Thiophenes/administration & dosage , Ticagrelor , Ticlopidine/administration & dosage , Ticlopidine/pharmacology , Treatment Outcome
2.
Bull Acad Natl Med ; 193(4): 895-904; discussion 905-7, 2009 Apr.
Article in French | MEDLINE | ID: mdl-20120280

ABSTRACT

Stress cardiomyopathy (Tako-Tsubo, Broken Heart syndrome, or apical ballooning syndrome) was recently recognized as a distinct clinical entity. The aims of this review are to define this acute and reversible cardiomyopathy and to list its major clinical, biological and angiographic features. We performed a Medline scan for all relevant case series. The studies thus identified suggest that the apical ballooning syndrome accounts for 2% of ST-elevation infarcts, mainly affects women, and occurs after major emotional or physical stress. Most patients present with chest pain and dyspnoea, cardiogenic shock and (or?) ventricular fibrillation. ST segment modifications and mildly elevated cardiac enzyme levels are reported in 81% of patients. Left ventricular dysfunction occurs in the absence of epicardial coronary artery obstruction and typically consists of a hyperkinetic basal region and an akinetic apical half of the ventricle. The in-hospital mortality rate is about 1.2%. Most patients recover fully after a few weeks. Norepinephrine concentrations are elevated in three-quarters of patients. This syndrome should be considered among the differential diagnoses in patients presenting with chest pain, and especially in post-menopausal women with a recent history of stress. In its broadest sense, this phenomenon may encompass a range of disorders, including left ventricular dysfunction following central nervous system injury. It should also be considered in women with acute coronary syndromes.


Subject(s)
Stress, Psychological/complications , Takotsubo Cardiomyopathy/etiology , Humans , Takotsubo Cardiomyopathy/diagnosis , Takotsubo Cardiomyopathy/physiopathology , Takotsubo Cardiomyopathy/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...